Schizophrenia/Psychosis

First-episode psychosis cases are presented here using the RAISE study model-individual sessions, family psycho-education, social advancement in school work, and an expert psychiatrist prescriber.

Is clozapine still the gold standard for treatment-resistant schizophrenia?

An introduction to our 2-part Special Report on eating disorders, including neurobiology of eating disorders, nutritional needs of patients, clinical response to psychosis, and more.

Do atypical antipsychotics increase the risk of major malformations among exposed infants?

Check out what's new in schizophrenia research, personality disorders, patient education, integrative psychiatry, addiction, and more.

For too long the treatment needs of the seriously mentally ill have been ignored by SAMSHA, and this needs to change, says this psychiatrist.

Both the literature and clinical experience point to considerable risk in discontinuing antipsychotic treatment, for many chronically psychotic patients. Here's why.

Editors' choices of noteworthy psychiatry stories from around the Web: genetics of schizophrenia, Alzheimer disease, the perils of mixing prescription and over-the-counter medications, new guidelines for treating pain with opioids, and other topics.

Reasons for the overall low rate of clozapine use brings to light questionable decisions on the part of policymakers

For a change, here is some very good news coming from several fronts. "It’s almost like science fiction, but it’s real."

The identification of a genetic risk factor has shed light on the underlying neurobiology of the disorder.

Groundbreaking work by a Harvard team represents a bold step in our journey toward understanding schizophrenia.

A simple handshake is no longer a formal gesture to symbolize parting ways. It has become that moment, with a patient, when we both agree to embark on a journey together.

Setting the record straight on what the literature does and does not say about long-term use of antipsychotics.

Brain-based biomarkers identify more biologically homogeneous categories of psychosis than do clinical diagnoses.

Are you up-to-date on the risk of recurrent pneumonia in patients with schizophrenia when an antipsychotic is reintroduced?

Editors' picks, including the biggest story of the year thus far and others of interest to psychiatrists and the public.

New evidence-coupled with advances in molecular biology-has afforded an unparalleled opportunity to move toward identifying potential new treatments for schizophrenia.

A report of initiatives that have raised awareness of and promoted data sharing and data transparency in order to advance science and improve public health and health care.

Neuroinflammation may be a culprit in the development of psychosis. What are the clinical implications?

How targeted interventions may reduce the burden of premature mortality among patients with schizophrenia and other psychiatric disorders.

How do the 3 FDA-approved dopamine receptor partial agonists for the treatment of MDD and other psychiatric disorders stack up against each other?

The first episode of psychosis represents a critical juncture in the treatment of schizophrenia. Here: A synopsis of 2-year outcomes from the NIMH Recovery After an Initial Schizophrenia Episode (RAISE) Early Treatment Program.

Information about the performance of clozapine compared with other treatment strategies in usual practice may impact on its use in routine clinical settings. Here: findings from US national Medicaid data in a cohort of patients with treatment-resistant schizophrenia.

Can mobile technologies advance care for schizophrenia? The research literature strongly supports feasibility, although clinical data on validity, safety, and efficacy are still lacking.